PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00 ...
Morgan Stanley lowered the firm’s price target on Arrowhead (ARWR) to $78 from $81 and keeps an Equal Weight rating on the shares. Broad pipeline execution continues with multiple readouts expected ...
Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Arrowhead (ARWR) to $70 from $45 and keeps an Overweight rating on the shares. The firm notes the FDA approved Arrowhead’s first ...
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results